Nexentis Subsidiary MitoCareX Achieves Drug Discovery Milestone with MITOLINE® Platform for Cancer and Inflammatory Disease Treatment
核心洞察
MitoCareX Bio (搜索) has successfully generated an optimized hit molecule with substantially improved pharmaceutical properties compared to its initial compound, marking a pivotal milestone in targeting mitochondrial SLC25 carrier proteins.
The proprietary MITOLINE® algorithm platform enabled identification of the initial hit molecule by generating reliable 3D structural models of mitochondrial carrier proteins, overcoming a central bottleneck in mitochondrial drug discovery.
The program targets hard-to-treat cancers and inflammatory metabolic diseases in markets projected to grow significantly, with cancer therapy reaching $447 billion by 2031 and anti-inflammatory drugs reaching $185 billion.
Nexentis Technologies (搜索) Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio (搜索) Ltd., has achieved its first drug discovery milestone since acquisition: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound. The milestone was assessed as of March 31, 2026, and represents a pivotal inflection point in MitoCareX's drug discovery program.
MITOLINE® Platform Overcomes Historical Drug Discovery Challenges
The achievement demonstrates that MitoCareX's proprietary MITOLINE® algorithm platform can power drug discovery and development progression in a target class that has historically been difficult to drug. MITOLINE®, a U.S. trademark-registered algorithm whose registration was announced by Nexentis in May 2026, enabled the identification of the program's initial hit molecule by generating reliable 3D structural models of a mitochondrial carrier protein in the SLC25 family.
This capability addresses a central bottleneck in mitochondrial drug discovery: the near-total absence of experimentally solved 3D structures for this important protein class. The initial hit was identified through MITOLINE®-enabled virtual screenings and has now undergone systematic medicinal chemistry optimization.
Targeting High-Value Therapeutic Areas
MitoCareX's program is advancing a novel small molecule drug candidate targeting a mitochondrial SLC25 carrier protein, developed to potentially address hard-to-treat cancers and inflammatory metabolic diseases. These therapeutic areas represent some of the most dynamic and capital-intensive spaces in global pharma.
According to Mordor Intelligence projections cited by the company, the cancer therapy market alone is projected to grow from approximately $270 billion in 2026 to nearly $447 billion by 2031, representing a compound annual growth rate of approximately 10.6%. The anti-inflammatory drugs market is projected to grow from approximately $129 billion in 2026 to $185 billion by 2031, growing at a CAGR of approximately 7.5%.
Within these markets, there remains a significant unmet need for novel, orally available small molecule therapies - the modality at the core of MitoCareX's discovery engine.
Enhanced Pharmaceutical Properties
The optimized hit molecule demonstrates clear improvements across key pharmaceutical parameters, with the company specifically noting demonstrated improvements in metabolic stability and drug-like properties. These enhancements bring MitoCareX meaningfully closer to generating a lead molecule for advancement to pre-clinical trials.
"Achieving our first drug discovery milestone since the acquisition of MitoCareX, is a testament to the power of the MITOLINE® platform and the quality of MitoCareX's drug discovery team," said David Palach, Chief Executive Officer of Nexentis Technologies (搜索). "MITOLINE® gave us the structural insight to identify a differentiated starting point for our medicinal chemistry program. The team has now built on that foundation by generating optimized molecules with demonstrated improvements in metabolic stability and drug-like properties - bringing us meaningfully closer to a lead molecule."
Path Forward
MitoCareX is advancing towards pre-clinical trials and generating a lead molecule, building on the structural and medicinal chemistry foundation established through the MITOLINE® platform. The company indicated it looks forward to advancing to its next milestones and continuing to potentially build value for shareholders.
Nexentis Technologies (搜索) Inc. owns 100% of MitoCareX Bio (搜索) Ltd., which is engaged in targeting cancer and inflammatory metabolic disease indications through the mitochondrial SLC25 protein family. Additionally, Nexentis has adopted an investment strategy focused on European renewable energy assets utilizing a Ready to Build (RTB) business model, currently serving as the lead investor in four solar projects across three European Union countries.